Wednesday, Eli Lilly and Company (LLY) announced results from two late-phase trials showing that people with obesity maintained their weight loss long term with either Foundayo or lower-dose Zepbound after switching from higher doses of injectable incretin therapy.
In SURMOUNT-MAINTAIN trial, both Zepbound MTD and Zepbound 5 mg met the primary and all key secondary endpoints, showing weight-loss maintenance after 60-weeks of initial treatment with Zepbound MTD.
Meanwhile, ATTAIN-MAINTAIN demonstrated that switching to Foundayo also supported long-term weight maintenance, meeting the primary and all key secondary endpoints using both the efficacy estimand and treatment-regimen estimand.
In the pre-market hours, LLY is trading at $988.10, down 0.17 percent on the New York Stock Exchange.
For comments and feedback contact: editorial@rttnews.com
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.